Analysts at Janney Capital Markets have lowered their 2014 and 2015 earnings estimates for Chiquita Brands International Inc. (NYSE:CQB), while maintaining a neutral rating on the stock. The firm has lowered its 2014 EPS to $1.01 from $1.12, and reduced its 2015 EPS forecast to $1.25 from $1.29 a share.

The estimate adjustment comes just a few days after Chiquita Brands International Inc. (NYSE:CQB) reported Q4 2013 EPS that fell well below analyst estimates due to weak North American banana pricing as a result of bad weather. “While we like everything we’ve seen from management and this likely temporary cyclical weakness in banana,” said Janney, “fundamentals could prove a good chance to accumulate for the long-term.” Shares of Chiquita Brands International Inc. (NYSE:CQB) are steady in pre-market activity at $10.94, and move within a 52-week spread of $5.90 – $13.68.

Analysts at BMO Capital have initiated coverage of biopharmaceutical company Revance Therapeutics Inc. (NASDAQ:RVNC) with an Outperform rating. The firm set its price target on the stock at $37 a share. In the pre-market session, shares of Revance Therapeutics Inc. (NASDAQ:RVNC) are flat at $26.93, within a 52-week range of $21 – $31.

Real estate investment trust Brandywine Realty Trust (NYSE:BDN) has been upgraded by analysts at BMO Capital to an Outperform rating from Market Perform. The price target has been set at $16.50 a share. In pre-market trading, shares of Brandywine Realty Trust (NYSE:BDN) are unchanged at $14.65, and move within a 52-week range of $12.23 – $16.06.

Sodastream International Ltd. (NASDAQ:SODA) has been downgraded by analysts at Barclays to an equalweight rating from overweight. The firm also lowered its price target by more than a quarter to $40 from $55 a share. In the pre-market session, shares of Sodastream International Ltd. (NASDAQ:SODA) are down 2.43% to $38.52, within a 52-week range of $35.27 – $77.80.

Analysts at MP Securities have initiated coverage of pharmaceutical company Egalet Corp. (NASDAQ:EGLT) with a market outperform rating and a $19 price target. Shares of Egalet (NASDAQ:EGLT) are steady in the pre-market session at $12.87, and trade within a 52-week range of $11.82 – $13.67.